FLT3LG and neoplasm: We administered a mixture of 1 × 106 DCP-IL-12 or moDC-IL-12, and 2 × 106 DCP-FLT3L or moDC-FLT3L, to mice with B16F10 tumors on days three and five following tumor challenge (Fig. 3a).